The global oncology market features several blockbuster drugs that generate multi-billion-dollar annual revenues due to their widespread clinical utility across various cancers. Prominent top-selling cancer medications include immune checkpoint inhibitors like Keytruda and Opdivo, targeted therapies like Revlimid and Imbruvica, and advanced monoclonal antibodies and antibody-drug conjugates utilized in treating breast, lung, blood, and gastrointestinal malignancies globally.